Abstract: The present invention provides an animal ectoparasite-controlling agent containing as an active ingredient a hydrazide compound represented by the formula (1) wherein R3 represents a fluorine atom, a chlorine atom, a bromine atom, a methyl group, an ethyl group or a hydrogen atom, R5 and R6 are the same or different each other and each represents a methyl group or a hydrogen atom, R4 represents a C1-C6 haloalkyl group, which shows excellent controlling effects on animal ectoparasites.
Abstract: The present invention relates to a novel anhydrous crystalline form of zofenopril calcium of formula (I), chemically known as (4S)-1-[(2S)-3-(benzoylthio)-2-methylpropionyl]-4-(phenylthio)-L-proline calcium salt or hemi-calcium salt. The present invention further relates to a process for the preparation of the new crystalline form of zofenopril calcium, its use in pharmaceutical compositions and the use of the new crystalline form and compositions in the treatment of hypertension and various other diseases.
Abstract: This invention describes methods and pharmaceutical compositions for combinational cancer treatments that are capable of inducing JNK phosphorylation and induce programmed cell death. It also identified genes as target for anti-cancer drug development and enhancement of the chemotherapeutic drug effect for the treatment of cancer. This invention points to a novel method and principle for a new avenue of developing more efficient and low or non cytotoxic cancer treatment.
Abstract: S-alkylsiothiouronium derivatives such as S-ethylisothiouronium diethylphosphate are used for the treatment of headaches, in particular, migraines, as well as for the prevention or treatment of nausea and vomiting. The compositions of the invention are also effective in preventing or alleviating emesis associated with migraines or other medical conditions such as chemotherapy or radiotherapy, as well as other symptoms of migraines including phonophobia and photophobia.
Abstract: The present invention relates to compounds of the formula I, in which R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
Type:
Grant
Filed:
October 5, 2009
Date of Patent:
March 11, 2014
Assignee:
Sanofi
Inventors:
Marc Nazare, Gernot Zech, Melitta Just, Tilo Weiss, Gerhard Hessler, Joerg Czech
Abstract: Disclosed herein are parenteral solutions containing 3-diethylaminoethoxy benzoyl-benzofurans, such as amiodarone, in a diluent NNDMA (N,N-Dimethylacetamide) useful in the treatment of cardiac arrhythmias both supraventricular, ventricular as well as, the condition of cardiac arrest.
Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.
Type:
Grant
Filed:
November 9, 2009
Date of Patent:
December 17, 2013
Assignee:
Intermune, Inc.
Inventors:
Williamson Ziegler Bradford, Javier Szwarcberg
Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.
Type:
Grant
Filed:
December 6, 2011
Date of Patent:
November 26, 2013
Assignee:
Intermune, Inc.
Inventors:
Williamson Ziegler Bradford, Javier Szwarcberg
Abstract: A method for the prevention of diseases caused by thrombus or embolus. The method is to separately administer 2-acetoxy-5-(?-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, in their pharmacologically effective amounts, to a warm-blooded animal.
Abstract: Nicotine receptor agonists or analogs or derivatives thereof for treating inflammatory pulmonary diseases, and pharmaceutical compositions including nicotine receptor agonists or analogs or derivatives thereof. Compounds of formula wherein R1, R2, Xa and Ya are as defined herein are also provided.
Type:
Grant
Filed:
July 26, 2011
Date of Patent:
October 15, 2013
Assignee:
Universite Laval
Inventors:
Yvon Cormier, Evelyne Israel-Assayag, Marie-Renee Blanchet, Rene C. Gaudreault, Philippe Labrie
Abstract: Nicotine receptor agonists or analogs or derivatives thereof for treating inflammatory pulmonary diseases, and pharmaceutical compositions including nicotine receptor agonists or analogs or derivatives thereof. Compounds of formula wherein R1, R2, Xa and Ya are as defined herein are also provided.
Type:
Grant
Filed:
July 8, 2011
Date of Patent:
October 8, 2013
Assignee:
Universite Laval
Inventors:
Yvon Cormier, Evelyne Israel-Assayag, Marie-Renee Blanchet, Rene C. Gaudreault, Philippe Labrie
Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.
Type:
Grant
Filed:
June 3, 2011
Date of Patent:
October 1, 2013
Assignee:
P2D, Inc.
Inventors:
Nigel H. Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William D. Figg
Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I), where V, W, R1, R2, R3 and R4 are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
Abstract: The subject invention provides materials and methods for improving alcohol metabolism in animals. In a preferred embodiment, the invention provides methods for increasing the ability of people to consume alcohol while reducing hangovers or other effects of intoxication. Specifically exemplified herein is the use of a cysteamine compound to reduce the adverse effects of alcohol consumption. For example, the undesirable and unpleasant symptoms association with hangovers can be reduced through consumption, according to the subject invention, of cysteamine hydrochloride.
Abstract: The invention relates to the use of purine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells, said derivatives being of formula (I): where R2, R6 and R9, independently=halogen, a R—NH—, R—NH—NH—, NH2—R?—NH or R—NH—R?—NH— group, where R=straight or branched chain saturated or unsaturated alkyl, aryl, cycloalkyl, or heterocyclyl group, R?=straight or branched chain, saturated or unsaturated alkylene, arylene or cycloalkylene, R and R? each include 1 to 8 carbon atoms optionally substituted with one or more —OH, halogen, amino or alkyl groups, R2 furthermore may be a heterocycle optionally with a straight or branched chain saturated or unsaturated alkyl, aryl or cycloaryl or a heterocycle optionally substituted by one or more —OH, halogen, amino or alkyl groups, R9 furthermore may be a straight or branched chain saturated or unsaturated alkyl, aryl or cycloalkyl and R2 and R9 furthermore may be hydrogen with the exception
Type:
Grant
Filed:
April 12, 2007
Date of Patent:
July 23, 2013
Assignees:
Centre National de la Recherche Scientifique-CNRS, Universite de Poitiers
Abstract: Disclosed herein are ways to solubilize aspirin for parenteral administration containing aspirin and a diluent NNDMA (N,N-Dimethylacetamide) useful in the treatment of acute coronary syndromes as well as other disease states. The solution so constituted is stable at room temperature for prolonged periods without decomposition and avoids significant hydrolysis of the aspirin and thus the loss of the anti-platelet action when stored.
Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
Type:
Grant
Filed:
June 11, 2009
Date of Patent:
May 21, 2013
Assignee:
Cytokinetics, Inc.
Inventors:
Bradley P. Morgan, David J. Morgans, Jr., Alex Muci, Pu-Ping Lu, Erica A. Kraynack, Todd Tochimoto
Abstract: Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.
Type:
Grant
Filed:
April 16, 2009
Date of Patent:
April 2, 2013
Assignee:
SANOFI
Inventors:
Davide Radzik, Martin Van Eickels, Nacéra Hamdani, Christophe Gaudin